SGCM
KDNY

Sand Grove Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Sand Grove Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-315,973
Closed -$12.1M – 40
2023
Q2 		$12.1M Buy
+315,973
New +$8.11M 1.42% 23

Sand Grove Capital Management's KDNY Position: Q3 2023 in Review

Sand Grove Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 315,973 shares — an estimated $12.1M sold.

Sand Grove Capital Management first reported a position in KDNY in Q2 2023 and held it in 1 quarter. The position peaked at $12.1M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Sand Grove Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Sand Grove Capital Management sold 315,973 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $12.1M.
  • Sand Grove Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Sand Grove Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $12.1M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Sand Grove Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.